FDA approves donanemab, now Kisunla, to treat early Alzheimer's
Eli Lilly's donanemab, now Kisunla, was approved by the U.S. Food and Drug Administration for patients with early symptomatic Alzheimer’s.| Alzheimer's News Today
Eli Lilly's donanemab, now Kisunla, was approved by the U.S. Food and Drug Administration for patients with early symptomatic Alzheimer’s.| Alzheimer's News Today
Leading many to question the state of Alzheimer's research as a whole.| moderndiscontent.substack.com
